Close

Roth Capital Bullish on Recent BioBlast Pharma (ORPN) Hires; Reaffirms at 'Buy'

November 17, 2015 9:00 AM EST
Get Alerts ORPN Hot Sheet
Price: $11.50 --0%

Rating Summary:
    2 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Join SI Premium – FREE

Roth Capital reaffirms BioBlast Pharma (Nasdaq: ORPN) with a Buy rating and $26 price target after ORPN announced the appointment of three new senior executives to its leadership team: Warren Wasiewski, M.D. as Chief Medical Officer and Vice President, Research & Development, Leigh Cherry as Vice President Manufacturing, and Stacey Jurchison as Vice President, Investor Relations & Corporate Communications. Recently, the company also announced the appointments of Paul Firuta as Chief Commercial Officer, and Theresa (Terri) Stevens as Chief Corporate Development Officer. All are U.S.-based positions with global responsibilities.

Analyst Joseph Pantginis commented on recent hires: We emphasize these hires as 1) support for our thesis anticipating rapid development of the orphan pipeline, 2) the company's full transition to development and commercialization phase and 3) establishment of the U.S. HQ footprint.

For an analyst ratings summary and ratings history on Bio Blast Pharma click here. For more ratings news on Bio Blast Pharma click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Management Changes

Related Entities

Roth Capital